KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Invested Capital (2016 - 2025)

Historic Invested Capital for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $18.3 billion.

  • Biogen's Invested Capital fell 1413.9% to $18.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.3 billion, marking a year-over-year decrease of 1413.9%. This contributed to the annual value of $18.3 billion for FY2025, which is 1413.9% down from last year.
  • Biogen's Invested Capital amounted to $18.3 billion in Q4 2025, which was down 1413.9% from $24.5 billion recorded in Q3 2025.
  • Biogen's Invested Capital's 5-year high stood at $24.5 billion during Q3 2025, with a 5-year trough of $17.2 billion in Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $20.4 billion (2023), whereas its average is $20.1 billion.
  • Data for Biogen's Invested Capital shows a peak YoY increase of 1716.31% (in 2025) and a maximum YoY decrease of 1413.9% (in 2025) over the last 5 years.
  • Over the past 5 years, Biogen's Invested Capital (Quarter) stood at $17.2 billion in 2021, then grew by 14.13% to $19.7 billion in 2022, then rose by 9.75% to $21.6 billion in 2023, then decreased by 1.5% to $21.3 billion in 2024, then fell by 14.14% to $18.3 billion in 2025.
  • Its Invested Capital stands at $18.3 billion for Q4 2025, versus $24.5 billion for Q3 2025 and $23.9 billion for Q2 2025.